Cristina Valencia Sanchez, M.D., Ph.D.

Closed for Enrollment

• A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Basket Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis (CIELO) Rochester, Minn., Scottsdale/Phoenix, Ariz.

  The purpose of this study is to assess the effectiveness, safety, pharmacokinetics, and pharmacodynamics of satralizumab in participants with anti--N‑methyl-D‑aspartic acid receptor (NMDAR) and anti--leucine‑rich glioma‑inactivated 1 (LGI1) encephalitis. 

   

• A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab as Monotherapy or In Addition to Baseline Therapy in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) (MOGAD) Rochester, Minn., Scottsdale/Phoenix, Ariz.

  The purpose of this study is to evaluate the effectiveness, safety, pharmacokinetics, and pharmacodynamics of satralizumab compared with placebo as monotherapy or in addition (add-on) to baseline/background ISTs for Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) relapse prevention.

   

• A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD) (cosMOG) Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

  The purpose of the study is to evalute the effectiveness, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD).